Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1692173

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Estradiol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the supply of Estradot patches for women with menopausal symptoms.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15964
answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>There are over 70 hormone replacement therapy (HRT) products licensed for supply in the United Kingdom. There have been issues with the supply of a limited number of HRT products, primarily due to very sharp increases in demand, but the supply position has improved considerably over the last year, following intensive work with industry. We have held roundtables, and continue to do so, with suppliers, wholesalers, and community pharmacists to discuss the challenges they are facing, and what needs to be done to address them.</p><p>Intermittent supply issues were affecting estradot patches, which resulted in the use of a Serious Shortage Protocol, to allow pharmacists to supply an alternative brand of estradiol patches where estradot patches were not available. However, the issues have now been resolved and supplies should be available. We are continuing to engage closely with the supplier to monitor the supply position and drive action.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 15965 question first answered 06/03/2024 17:16:54 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1692174

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Estradiol
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help resolve supply chain issues for Estradot patches; and whether she has made an assessment of the potential impact of the UK’s withdrawal from the EU on such supplies.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15965
answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>There are over 70 hormone replacement therapy (HRT) products licensed for supply in the United Kingdom. There have been issues with the supply of a limited number of HRT products, primarily due to very sharp increases in demand, but the supply position has improved considerably over the last year, following intensive work with industry. We have held roundtables, and continue to do so, with suppliers, wholesalers, and community pharmacists to discuss the challenges they are facing, and what needs to be done to address them.</p><p>Intermittent supply issues were affecting estradot patches, which resulted in the use of a Serious Shortage Protocol, to allow pharmacists to supply an alternative brand of estradiol patches where estradot patches were not available. However, the issues have now been resolved and supplies should be available. We are continuing to engage closely with the supplier to monitor the supply position and drive action.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 15964 question first answered 06/03/2024 17:16:54 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4510 label Biography information for Helen Hayes

1692175

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Menopause: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the average waiting time for cognitive behavioural therapy for women with menopausal symptoms in London.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	15966
answer	answer is ministerial correction date of answer 05/03/2024 answer text <p>Improving care and support for menopause is a priority in the Women’s Health Strategy. It is important that all women experiencing the menopause have access to information and options to enable them to choose the best care to suit them. The National Institute for Health and Care Excellence’s guidelines currently recommend that that cognitive behavioural therapy (CBT) can be recommended for low mood or anxiety that arises as a result of the menopause.</p><p>CBT is offered as part of the NHS Talking Therapies services. The latest data for NHS Talking Therapies in the London region shows that 35,410 females, including trans women, accessed National Health Service funded treatment during the period from October to December 2023. Of these, 91% completing treatment waited less than six weeks for their first appointment, against a target of 75%, and 98% completing treatment waited less than 18 weeks, against a target of 95%. Data is not collected separately for CBT, which is one type of talking therapy. Data is also not collected separately for females with menopausal symptoms. This data is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-monthly-statistics-including-employment-advisors/performance-december-2023-and-quarter-3-2023-24-data" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-monthly-statistics-including-employment-advisors/performance-december-2023-and-quarter-3-2023-24-data</a></p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 05/03/2024 11:57:12 answering member 4492 label Biography information for Maria Caulfield
tabling member	4510 label Biography information for Helen Hayes